"rationale","description","label","id","uuid:ID","name","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","","StudyDesign_1","e59be00f-09b3-4eea-aeed-d2b9655d4e35","Study Design 1","StudyDesign"
